These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Meningococcal vaccines: from polysaccharide to conjugate vaccines]. Cohen R; Levy C Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368 [TBL] [Abstract][Full Text] [Related]
3. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment. Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749 [TBL] [Abstract][Full Text] [Related]
4. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia. Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958 [TBL] [Abstract][Full Text] [Related]
6. Meningococcal vaccine evolution. Bona G; Guidi C J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617 [TBL] [Abstract][Full Text] [Related]
7. Meningococcal disease: a review on available vaccines and vaccines in development. Bröker M; Fantoni S Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565 [TBL] [Abstract][Full Text] [Related]
8. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE; MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099 [TBL] [Abstract][Full Text] [Related]
9. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients. Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691 [TBL] [Abstract][Full Text] [Related]
10. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Pace D Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410 [TBL] [Abstract][Full Text] [Related]
11. [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations]. Gendrel D Arch Pediatr; 2012 Sep; 19 Suppl 2():S70-6. PubMed ID: 22883370 [TBL] [Abstract][Full Text] [Related]
12. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial. van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575 [TBL] [Abstract][Full Text] [Related]
13. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease. Hellenbrand W; Koch J; Harder T; Bogdan C; Heininger U; Tenenbaum T; Terhardt M; Vogel U; Wichmann O; von Kries R Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1314-43. PubMed ID: 26487381 [TBL] [Abstract][Full Text] [Related]
14. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504 [TBL] [Abstract][Full Text] [Related]
15. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. Trotter CL; Ramsay ME FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998 [TBL] [Abstract][Full Text] [Related]
16. Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine. Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Oster P; Borrow R Vaccine; 2014 Sep; 32(43):5715-21. PubMed ID: 25151042 [TBL] [Abstract][Full Text] [Related]
17. MenACWY-TT vaccine for active immunization against invasive meningococcal disease. Papaevangelou V; Spyridis N Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT. Findlow H; Borrow R Adv Ther; 2013 May; 30(5):431-58. PubMed ID: 23712402 [TBL] [Abstract][Full Text] [Related]
19. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906 [TBL] [Abstract][Full Text] [Related]
20. Meningococcal vaccination in pregnancy. Abu Raya B; Sadarangani M Hum Vaccin Immunother; 2018 May; 14(5):1188-1196. PubMed ID: 29485347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]